← Leaderboards
Judith S Leopold
University Of Michigan At Ann Arbor
$7,991,997
Attributed
$10,486,176
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,486,176 · 10
By mechanism
R01$6,572,894 · 3
R44$1,861,575 · 1
R21$768,307 · 2
R41$724,111 · 2
P30$559,289 · 2
Top collaborators
- Alnawaz Rehemtulla5 shared
- Christopher Emil Whitehead5 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Charles L Brooks$24,424,911
- Shaomeng Wang$36,139,079
- Mats Ljungman$9,091,730
- Vaibhav Sahai$809,149
- Diane M Simeone$15,596,624
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalPathway InteractionsDesignClinical TrialsMalignant NeoplasmsKras2 GenePhosphotransferasesSignal TransductionTumorBaseSurvival RateEffective TherapyFutureMutationResponseDoseClinically RelevantSmall MoleculeIn VivoPharmaceutical PreparationsMolecularMutateLeadEpidermal Growth Factor Receptor
Grant awards (36)
Developmental Therapeutics (DT)$71,754
P30 · FY2025 · CA · contact PI
Developmental Therapeutics (DT)$69,015
P30 · FY2024 · CA · contact PI
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$474,721
R01 · FY2023 · CA · contact PI
Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers$178,679
R21 · FY2023 · CA · contact PI
Developmental Therapeutics (DT)$70,520
P30 · FY2023 · CA · contact PI
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$474,721
R01 · FY2022 · CA · contact PI
Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer$427,589
R01 · FY2022 · CA · contact PI
Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers$218,790
R21 · FY2022 · CA · contact PI
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers$149,608
R41 · FY2022 · CA
Developmental Therapeutics (DT) Program$62,870
P30 · FY2022 · CA · contact PI
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$484,410
R01 · FY2021 · CA · contact PI
Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer$436,315
R01 · FY2021 · CA · contact PI
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers$299,503
R41 · FY2021 · CA
Developmental Therapeutics (DT) Program$64,041
P30 · FY2021 · CA · contact PI
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer$973,003
R44 · FY2020 · CA
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$484,410
R01 · FY2020 · CA · contact PI
Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer$454,941
R01 · FY2020 · CA · contact PI
Developmental Therapeutics (DT) Program$64,041
P30 · FY2020 · CA · contact PI
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer$888,572
R44 · FY2019 · CA
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$484,410
R01 · FY2019 · CA · contact PI
Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer$457,270
R01 · FY2019 · CA · contact PI
Developmental Therapeutics (DT) Program$64,039
P30 · FY2019 · CA · contact PI
Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer$496,769
R01 · FY2018 · CA · contact PI
Developmental Therapeutics (DT) Program$64,007
P30 · FY2018 · CA · contact PI
Developmental Therapeutics (DT) Program$9,970
P30 · FY2018 · CA · contact PI
Developmental Therapeutics (DT) Program$8,972
P30 · FY2018 · CA · contact PI
Developmental Therapeutics (DT) Program$7,661
P30 · FY2018 · CA · contact PI
Developmental Therapeutics (DT) Program$2,399
P30 · FY2018 · CA · contact PI
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer$275,000
R41 · FY2017 · CA
Design of MEK Inhibitor Regimens for the Treatment of Pancreatic Cancer$376,406
R01 · FY2016 · CA · contact PI
Co-Targeting CDK4 and MEK for Metastatic Colorectal Cancer Therapy$168,563
R21 · FY2016 · CA · contact PI
Design of MEK Inhibitor Regimens for the Treatment of Pancreatic Cancer$406,091
R01 · FY2015 · CA · contact PI
Co-Targeting CDK4 and MEK for Metastatic Colorectal Cancer Therapy$202,275
R21 · FY2015 · CA · contact PI
Design of MEK Inhibitor Regimens for the Treatment of Pancreatic Cancer$387,649
R01 · FY2014 · CA · contact PI
Design of MEK Inhibitor Regimens for the Treatment of Pancreatic Cancer$363,676
R01 · FY2013 · CA · contact PI
Design of MEK Inhibitor Regimens for the Treatment of Pancreatic Cancer$363,516
R01 · FY2012 · CA · contact PI